Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Brezinschek, HP; Rainer, F; Brickmann, K; Graninger, WB.
B lymphocyte-typing for prediction of clinical response to rituximab.
Arthritis Res Ther. 2012; 14(4):R161-R161
Doi: 10.1186/ar3901
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Brezinsek Hans-Peter
- Co-Autor*innen der Med Uni Graz
- Brickmann Kerstin
- Graninger Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The prediction of therapeutic response to rituximab in rheumatoid arthritis is desirable. We evaluated whether analysis of B lymphocyte subsets by flow cytometry would be useful to identify non-responders to rituximab ahead of time. Fifty-two patients with active rheumatoid arthritis despite therapy with TNF-inhibitors were included in the national rituximab registry. DAS28 was determined before and 24 weeks after rituximab application. B cell subsets were analyzed by high-sensitive flow cytometry before and 2 weeks after rituximab administration. Complete depletion of B cells was defined as CD19-values below 0.0001 x10⁹ cells/liter. At 6 months 19 patients had a good (37%), 23 a moderate (44%) and 10 (19%) had no EULAR-response. The extent of B lymphocyte depletion in peripheral blood did not predict the success of rituximab therapy. Incomplete depletion was found at almost the same frequency in EULAR responders and non-responders. In comparison to healthy controls, non-responders had elevated baseline CD95⁺ pre-switch B cells, whereas responders had a lower frequency of plasmablasts. The baseline enumeration of B lymphocyte subsets is still of limited clinical value for the prediction of response to anti-CD20 therapy. However, differences at the level of CD95⁺ pre switch B cells or plasmablasts were noticed with regard to treatment response. The criterion of complete depletion of peripheral B cells after rituximab administration did not predict the success of this therapy in rheumatoid arthritis.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal, Murine-Derived - pharmacology Antibodies, Monoclonal, Murine-Derived - therapeutic use
- Antirheumatic Agents - pharmacology Antirheumatic Agents - therapeutic use
- Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy
- B-Lymphocytes - drug effects B-Lymphocytes - metabolism
- Cohort Studies -
- Female -
- Humans -
- Male -
- Middle Aged -
- Predictive Value of Tests -
- Registries -
- Rituximab -
- Treatment Outcome -